Discovery of novel non-peptidic and non-covalent small-molecule 3CL^(pro)inhibitors as potential candidate for COVID-19 treatment  

作　　者：Zhidong Jiang Bo Feng Yumin Zhang Tianqing Nie Hong Liu Jia Li Haixia Su Leike Zhang Yi Zang Yu Zhou 

机构地区：[1]School of Life Science and Technology,ShanghaiTech University,Shanghai,201203,China [2]Lingang Laboratory,Shanghai,201203,China [3]Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China [4]Shenyang Pharmaceutical University,Shenyang,110016,China [5]State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,430071,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第6期2467-2470,共4页信号转导与靶向治疗（英文）

基　　金：supported by the National Natural Science Foundation of China(82151219,82130105);the Strategic Priority Research Program of the Chinese Academy of Sciences(SIMM010109,SIMM010111);the Qiusuo Outstanding Youth Project of Lingang Laboratory(LG-QS-202205-02).

摘　　要：Dear Editor,The global coronavirus disease 2019(COVID-19)pandemic,which is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has brought a profound impact on humanity.SARS-CoV-2 enters host cells through the interaction of its spike glycoprotein with angiotensin-converting enzyme 2(ACE2)of the host and releases its viral RNA genome.^(1)

关 键 词：ACE2 acute RESPIRATORY 

分 类 号：R563.1[医药卫生—呼吸系统]